Groundbreaking allogeneic, 'off-the-shelf' CAR-NK Platform targeting oncology and solid tumors

About Us

NAKI Therapeutics is an innovative research-focused biopharmaceutical company.  Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.

Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.

To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand ‘memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity. 

Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care.

Two microscopic views of CAR-NK cell rapid response to tumor antigen, illustrating CAR-NK cell therapy’s potential in solid tumor treatment.

Latest Publications

Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways…

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma…


Basic Natural Killer (NK) Cell Immunobiology

  1. Conventional NK cells are defined as CD3Negative and CD56positive populations in peripheral blood.
  2. NK cells are essential for the control of tumor cells or virally infected cells.
  3. NK cells are an integral part of the immune system, bridging innate and adaptive immunity.
  4. NK and CAR-NK cells can be used as potential ‘off-the-shelf’ cell products.


NAKI’s CD147-CAR-NK technology is:

  1. Novel: mechanism-based target HCC by CD147-CAR-NK.
  2. Safer: NK and CAR-NK cell therapy is known to have lower toxicity versus CAR-T.
  3. Strong pre-clinical data: published in Nature Communications (Sep 2020).

CAR-NK cells are a promising cell therapy. The reasons can be proposed as follows:

  • CAR-NK cell immunotherapy is less toxic.
  • CAR-NK cells have the potential to be used as an ‘off-the-shelf’ universal CAR product.
  • NAKI Therapeutics has developed a novel technology to expand “memory-like” CAR-NK cells by enriching CAR-NK metabolic pathways, which significantly enhances the persistence of CAR-NK cells in vivo.